Case series and clinical analysis of 14 cases of catastrophic antiphospholipid syndrome.
- Author:
Jie Yu GU
1
;
Cui LU
2
;
Hui SHI
1
;
Cheng De YANG
1
Author Information
1. Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
2. Department of Rheumatism, Central Hospital of Songjiang District, Shanghai 201600, China.
- Publication Type:Journal Article
- MeSH:
Antibodies, Antiphospholipid;
Antiphospholipid Syndrome/therapy*;
Catastrophic Illness;
Humans;
Lupus Coagulation Inhibitor;
Retrospective Studies;
Thrombosis/etiology*
- From:
Journal of Peking University(Health Sciences)
2018;50(6):1033-1038
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:Catastrophic antiphospholipid syndrome (CAPS), also known as Asherson's syndrome, is a special subtype of antiphospholipid syndrome (APS) characterized by multiple intravascular thrombosis involving multiple organs systems or tissues simultaneously or continuously, high titer antiphospholipid antibodies and high mortality rate. This article's aims was to analyze the clinical manifestation, laboratory examination and treatment therapy of CAPS for the purpose of improving the understanding, diagnosis and treatment of the disease in clinical practice.
METHODS:Retrospective analysis and descriptive statistics were applied to the clinical manifestations and laboratory findings of 14 CAPS cases from APS Shanghai Database (APS-SH) with catastrophic antiphospholipid.
RESULTS:Of the 14 CAPS patients, 12 cases satisfied the 2003 CAPS Classification Criteria accepted in the 10th International Congress on Antiphospholipid Antibody, and were diagnosed as definite APS and 2 cases were diagnosed as probable CAPS. Three cases were categorized as primary APS and 11 as APS secondary to systemic lupus erythematosus (SLE). Infection was mostly commonly seen before the onset of CAPS, followed by SLE activity and surgery. Among the involved organs, systems and tissues, brain and lung were most commonly affected sites of arterial thrombosis while peripheral vein was most commonly affected in venous thrombosis events among the clinical events. Triple positivity of anticardiolipin antibody (aCL), anti-β2 glyeoprotein I antibody (aβ2GPI), lupus anticoagulant (LA) were detected in 54.55% of the patients. Thrombocytopenia and decreased hemoglobin were frequently seen in the CAPS patients, and the majority proved to be hemolytic anemia. Of all the cases, 6 ended with death. The triple therapy strategy (anticoagulants, glucocorticoid, intravenous immunoglobulin and/or plasma exchange) could help to improve prognosis, cyclophosphamide and rituximab might benefit the patients with other comorbidities such as SLE and micro-angiopathic hemolytic anemia (MHA).
CONCLUSION:CAPS patients suffer from life-threatening acute multiple small vessel thrombosis with high titer of antiphospholipid antibody, potentially leading to multiple organ failure and a poor prognosis, thus early diagnosis and sufficient treatment are critical to prevent the progression of disease and improve the prognosis.
